Hirtle Callaghan & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Hirtle Callaghan & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-112	Closed	-$17K	–	215
2017 Q3	$17K	Hold	112	–	–	﹤0.01%	161
2017 Q2	$14K	Sell	112 -26	-19%	-$3.13K	﹤0.01%	153
2017 Q1	$16K	Hold	138	–	–	﹤0.01%	155
2016 Q4	$10K	Sell	138 -80	-37%	-$6.51K	﹤0.01%	141
2016 Q3	$19K	Hold	218	–	–	﹤0.01%	173
2016 Q2	$19K	Sell	218 -375	-63%	-$32.4K	﹤0.01%	154
2016 Q1	$46K	Sell	593 -86	-13%	-$7.78K	0.01%	135
2015 Q4	$86K	Hold	679	–	–	0.02%	100
2015 Q3	$70K	Hold	679	–	–	0.01%	144
2015 Q2	$84K	Buy	+679	New	+$85.6K	0.03%	146
2013 Q4	–	Sell	-6	Closed	–	–	655
2013 Q3	$0	Buy	+6	New	+$477	﹤0.01%	636

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Hirtle Callaghan & Co's VRTX Position: Q4 2017 in Review

Hirtle Callaghan & Co sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 112 shares — an estimated $17K sold.

Hirtle Callaghan & Co first reported a position in VRTX in Q3 2013 and held it in 11 quarters. The position peaked at $86K in Q4 2015. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

Hirtle Callaghan & Co reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Hirtle Callaghan & Co sold 112 Vertex Pharmaceuticals shares in Q4 2017, an estimated $17K.
Hirtle Callaghan & Co first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 11 quarters.
Hirtle Callaghan & Co's Vertex Pharmaceuticals position peaked at $86K in Q4 2015.
644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2017, filed 17 Jan 2018.